Latest Clinical Trials
Genomic profiling for cholangiocarcinoma and other cancers demonstrates significant evidence-based benefits, but faces practical hurdles.
Over the last decade, medical research has led to significant progress in the diagnosis and treatment of perihilar cholangiocarcinoma.
Disease progression has a major impact on outcomes in patients with intrahepatic cholangiocarcinoma and many factors influence recurrence-free survival, studies have found.
Many are heralding radiomics as the “next big thing” that will revolutionize medicine. We examine this claim, particularly when it comes to cholangiocarcinoma treatment.
Researchers explain the specific challenges of diagnosing and managing iCCA, and why a multidisciplinary approach works best.
We explore the risk factors associated with the various subtypes of cholangiocarcinoma and discuss their reliability.
Various medical imaging tools can play key roles in the detection, diagnosis, and monitoring of cholangiocarcinoma.
Dr. Reham Abdel-Wahab of the Cholangiocarcinoma Foundation says a raft of FDA-approved therapies and ongoing clinical trials will expand treatment options.
Eliminating geographic and ethnic bias in clinical trials for rare diseases is the goal of Jeeva Informatics, says founder and CEO Harsha K. Rajasimha, PhD.
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
Melinda Bachini, 52, never intended to be a patient advocate for a disease few people have ever heard of, let alone pronounce. But a 2009 diagnosis of cholangiocarcinoma changed everything for the mother of 6.
Rare Care Podcast